POINT Biopharma Global Inc. (NasdaqCM: PNT)
Health Care · Biotechnology · US
$—
— today · — 1Y
POINT Biopharma Global Inc. (NasdaqCM: PNT) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores POINT Biopharma Global Inc. across four factors: quality 54/100. Its strongest factor is quality.
PNT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $243.69M
- P/E
- —
- EPS
- 0.90
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 129
- Next earnings
- —
About POINT Biopharma Global Inc.
POINT Biopharma Global Inc. functions as a radiopharmaceutical company dedicated to the advancement and commercialization of specialized radioligand therapies designed to combat various cancerous conditions. Its two primary investigational treatments, both currently in Phase III clinical trials, are PNT2002, a radioligand engineered to target prostate-specific membrane antigen (PSMA) for addressing metastatic castration-resistant prostate cancer, and PNT2003, a somatostatin-targeted radioligand being evaluated for the treatment of neuroendocrine tumors. Beyond these late-stage programs, the company's pipeline includes earlier-stage product candidates such as PNT2001, a next-generation PSMA-targeting agent undergoing preclinical studies for non-metastatic castration-sensitive prostate cancer, and PNT-2004, a program focused on fibroblast activation protein-alpha (FAP-a) with broad potential across multiple tumor types, also in preclinical development. Additionally, POINT Biopharma is actively developing further drug candidates utilizing its CanSEEK technology, which it has sub-licensed from Bach Biosciences LLC and Avacta Life Sciences Limited. The company was established in 2019 and is headquartered in Indianapolis, Indiana.
- ISIN
- US7305411099
- Founded
- 2019
- Listed since
- Jul 8, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.29 | +0.67% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.02 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.42 | +1.14% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $555.26 | +1.40% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $837.90 | +1.13% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.60 | +13.47% |
Figures last refreshed Aug 18, 2026.